SEC Form 4 · accession 0001209191-18-057931
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Troy Edward Wilson
Officer — President and CEO · Director
Period of report
Nov 6, 2018
Accepted (ET)
Nov 9, 2018 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 6, 2018 | M | 26,041 | $4.80 | A | 59,026 | D | |
| Common Stock | holding | — | — | — | 1,735,991 | I | by Red Fish Blue Fish Revocable Trust | |
| Common Stock | holding | — | — | — | 406,736 | I | by Araxes Pharma LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF2 | $4.80 | Nov 6, 2018 | M | 26,041 | D | — | Jan 28, 2026 | Common stock | 26,041 | 65,974 | D |
Explanation of responses
- F1Represents options exercised
- F2This option vests in 48 equal monthly installments commencing on 1/29/2016.